必特 可利霉素片 CARRIMYCIN TABLETS
可利霉素为我国首个利用合成生物学技术自主研发成功的抗感染新药，研发过程是产、学、研紧密结合的典型。可利霉素对革兰氏阳性菌有较强的活性，对红霉素和β-内酰胺类抗生素耐药菌等亦有抗菌活性;与同类药没有完全交叉耐药性;并有较高的亲脂性，口服吸收快，组织渗透性强，分布广，体内维持时间长，有较好的抗生素后效应。Ⅲ期临床试验结果已证实可利霉素的临床疗效和安全性。
CARRIMYCIN TABLETS is the first new anti infective drug independently developed by using synthetic biology technology in China. The research and development process is typical of the close combination of production, learning and research. Colimycin has strong activity against gram-positive bacteria, as well as against erythromycin and β- Lactam antibiotic resistant bacteria also have antibacterial activity; Not completely cross resistant to similar drugs; And it has high lipophilicity, fast oral absorption, strong tissue permeability, wide distribution, long maintenance time in the body, and good post antibiotic effect. The results of the Phase III clinical trial have confirmed the clinical efficacy and safety of clindamycin.
Sales consultation hotline: 13048014500 (WeChat)
website: http://www.gzcrmi.com
Medication Tips
This content is for reference only, please refer to the instructions for details
character
This product is a film coated tablet, which appears white or almost white after removing the film coating.
产品介绍
This product is suitable for the treatment of mild to moderate community acquired infections in adults caused by sensitive bacteria:
1. Acute tracheobronchitis: Acute tracheobronchitis caused by Haemophilus influenzae and Streptococcus pneumoniae;
2. Acute sinusitis: Acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Moraxella catarrhalis, and Staphylococcus.
It should be noted that bacterial culture and drug sensitivity tests should be conducted before administration to identify the pathogenic bacteria and their sensitivity to colimycin. After collecting samples, the use of colimycin can be started for treatment, and corresponding adjustments can be made after obtaining the drug sensitivity results. To reduce the production of drug-resistant bacteria and maintain the effectiveness of colimycin and other antibacterial drugs, colimycin should only be used for the treatment of mild to moderate community acquired infections caused by sensitive bacteria or highly suspected sensitive bacteria. If culture and drug sensitivity data are obtained, consideration should be given when selecting or adjusting antimicrobial therapy. If these data are not available, local epidemiological and drug sensitive data can assist in selecting empirical treatments.
Based on existing research data, the recommended dosage for adult use is as follows: acute tracheobronchitis: oral, taken after meals. Adults should take a 0.4 g daily dose on the first day and a 0.2 g daily dose on days 2-7. Acute sinusitis: Take orally and after meals. Adults should take a 0.4 g daily dose on the first day and a 0.2 g daily dose on days 2-7.
National Drug Administration Standard YBH01512019
Guoyao Zhunzi H20190029 国药准字H20190029
Shanghai Tonglian Pharmaceutical Co., Ltd
